Plain English Summary
Background and study aims
It is very important that any side effects or symptoms people have during clinical trials are reported. Doing this helps researchers to see how safe a treatment is. It also contributes to guidelines on how to prescribe a drug, and to information for patients. In this study, researchers are developing a questionnaire that can be filled out from home using the internet or telephone to report these symptoms and side effects. This means any problems can be recorded straight away, rather than waiting until the next clinic appointment. This project is testing whether an electronic system (using the internet or telephone) is acceptable and used by cancer patients receiving treatment to report any symptoms, side effects and their quality of life on a regular basis during a 3 month period. The research team have already spoken to patients about what types of questions to ask and this stage of the project aims to see how the system will work in practice for example whether patients use the system and how they find using it.
What does the study involve?
Patients are approached during their routine hospital appointments. The researcher explains the different ways of completing the symptom/quality of life questionnaires from home using the internet and/or telephone. Basic training is given on how to use the systems. Patients will be asked to log in to one of the systems from home once a week for three months to answer questions about their symptoms and side effects. Once a month they are also be asked to complete some extra questions about their general quality of life. At the end of the study, patients may also be asked to take part in an interview or complete a feedback form to find out what they thought about the research and the symptom reporting system they used.
What are the possible benefits and risks of participating?
There are no immediate direct benefits to those taking part in this study, but the results will be used to help people with cancer in the future. We do not anticipate there to be any risks of taking part in this study it will not affect the usual care or treatment patients receive in any way. The study is not replacing usual care so all symptoms and side effects should continue to be reported to clinical teams in the usual way (e.g. emergency contacts).
Where is the study run from?
St James's University Hospital, St James's Institute of Oncology (Leeds, UK)
When is the study starting and how long is it expected to run for?
July 2014 to January 2016
Who is funding the study?
Cancer Research UK
Who is the main contact?
Dr Fiona Kennedy
Dr Fiona Kennedy
St James's Institute of Oncology
REPORT-UK: Pilot study to assess feasibility and compliance of electronic based system for patients to remotely self-report AEs and other PROMs in UK cancer clinical trials
REPORT-UK: Phase 3 pilot study
Reporting of adverse events (AEs) is essential in clinical trials. The current system for reporting AEs, the Common Terminology Criteria for Adverse Events (CTCAE), relies on the clinicians interpretation of patient symptoms. The importance and added value of patient self-reports of AEs and Patient Reported Outcome Measures (PROMs) has been recognised by clinicians, regulatory authorities and health-care commissioners, but robust and cost-effective data collection methods are needed. This project is part of a research programme aiming to develop, introduce and evaluate the feasibility and acceptability of an electronic system for patients to remotely self-report AEs and other PROMs in UK cancer clinical trials (REPORT-UK).
Aims and objectives:
1. To evaluate feasibility and patient compliance with using an internet-based or telephone-based system for collecting patient-reported AEs data and other PROMs (EORTC QLQ-C30)
2. To report the proportion of expected weekly AE reports completed
3. To test the complete IT platform including the patient and research staff interface, and the integration of REPORT-UK data with a standard clinical trial database
4. To explore implementation issues through patient and staff interviews
We aim to recruit a sample of 252 cancer patients from St Jamess University Hospital, Leeds and University Hospitals Bristol NHS Foundation Trust with either early or metastatic disease receiving chemotherapy, targeted agents, hormonotherapy, radiotherapy or surgery. Participants will be asked to take part in a prospective longitudinal study involving electronic (internet/IVRS) completion of self-reports for up to 3 months during treatment.
Participants will be asked to complete weekly symptom reports (21 common symptom questions) via their chosen method (internet and/or IVRS). Once a month participants will also be asked to complete quality of life (EORTC QLQ-C30). Interviews with participants and staff will take place at the end of the study.
Yorkshire & The Humber Leeds East, 18/06/2014, ref. 14/YH/0181
Validation of investigative therapeutic process
Primary study design
Secondary study design
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Topic: Cancer; Subtopic: All Cancers/Misc Sites; Disease: All
Patients will complete weekly AEs from home and monthly QOL via internet or telephone IVRS. Reports on AEs will be attached to medical notes for clinicians. Follow Up Length: 3 month(s)
Primary outcome measures
1. Number of patients potentially eligible, number recruited and reasons for non-recruitment; Timepoint(s): End of study
Secondary outcome measures
1. Number of and timing of participant withdrawals from follow-up data collection and reasons for withdrawal; Timepoint(s): End of study
2. Proportion of expected weekly AE reports completed; Timepoint(s): End of study
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Cancer patients undergoing treatment with curative or palliative intent within the following treatment groups and corresponding cancer sites:
1.1. Chemotherapy: breast, ovarian, bladder, colorectal, leukaemia
1.2. Targeted agents (tyrosine kinase inhibitors, monoclonal antibodies): renal, myeloma, lymphoma, leukaemia, advanced breast cancer
1.3. Hormonotherapy: breast, prostate
1.4. Radiotherapy or chemoradiotherapy: prostate, lung, head and neck, oesophageal, rectal
1.5. Surgery: oesophageal, gastric, pancreas, liver resections, colorectal, lung
2. Patients receiving chemotherapy must be within their first two cycles of treatment
3. Patients receiving radiotherapy must be at the beginning of their treatment
4. Patients scheduled for surgery or within 1 month of discharge postsurgery
5. Able and willing to give informed consent
6. Able to read and understand English
7. Access to a touch tone telephone and/or computer with internet
8. Aged 18 years or over; Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified
Target number of participants
Planned Sample Size: 252; UK Sample Size: 252
Participant exclusion criteria
1. Patients under the age of 18
2. Patients with overt exhibition of psychopathology or serious cognitive dysfunction which would impede study participation
3. Patients taking part in another clinical trial where there is a requirement to complete extensive quality of life questionnaires
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
University Hospital Bristol NHS Foundation Trust
St James's Institute of Oncology
University of Leeds (UK)
Cancer Research UK; Grant Codes: C7775/A14384
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
To be confirmed at a later date
Intention to publish date
Participant level data
Available on request
Results - basic reporting